anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The problems of social inequalities in access to care are major public health issues as recalled by the Regional Health Agency (ARS) of French Guiana in the Regional Health Project (PRS). French Guiana has high precariousness indicators with half of its population living below the poverty line. In addition, health indicators are often more degraded in precarious populations. Thus, in French Guiana, there is a higher rate of premature mortality, partly attributable to obesity, sedentary lifestyle, diabetes and hypertension than in mainland France. Despite an increased need for follow-up of chronic pathologies, the precarious population faces many difficulties in accessing care. The Permanent Access to Health Care (PASS) in Cayenne is a medico-social system, created to respond to these problems. The PASS allows access to monitoring of chronic diseases and support towards the common law healthcare system. Although the phenomenon of non-use of care studied in the precarious population of western French Guiana seems primarily attributable to the absence of social security. The main objective is to evaluate the use of the common law system in hypertensive or diabetic patients treated at the PASS in Cayenne. In addition, the investigators want to study the relationship between integration into the system and the socio-demographic, medical characteristics, understanding of health monitoring.
Effects of systematic cervical exam training on Labor and Delivery care Patient will be approached to obtain consent for them to have 2 cervical exams performed one after the other when an exam is clinically indicated. The discrepancy between the 2 examiners will be compared between the 6 month time period before the unit wide training and 6 months after completion of the training.
PURPOSE:A cosmetic that contains, as an active ingredient, germanium dioxide and is prepared into a solution or cream and allowed to soak into hair roots under skins to give oxygen sufficiently to improve the nutritive conditions of hair roots whereby dandruff and hair-falling are prevented and hair growth is promoted. CONSTITUTION:The objective hair tonic cosmetic contains germanium dioxide as an active ingredient. For example, it is prepared by using 40mg of germanium dioxde, 240ml of ethanol; 180ml of glycerol and 1,000ml of purified water. It is used in such a manner as the cosmetic is applied to hair 2 or 3 times a day, after the hair is made clean, rubbed and hair is done. When the repitition is continued for several days, dandruff and itching stop and hair-falling reduces after about a week and the formation of new hair roots are observed 6-7 weeks later. It is caused by the aqueous solution of germanium dioxide.
An information processing apparatus includes an association unit and an output control unit. The association unit associates a scheduled operation described in an operation-plan document with a scheduled operation of the same. The operation-plan document is an electronic document describing one or more scheduled operations that are to be performed during a predetermined period. The document describes one or more scheduled operations that are extracted to be performed during a period shorter than the predetermined period and one or more handwritten operation records each of which corresponds to scheduled operations described in the document. The output control unit performs control to output a scheduled operation that is associated with the scheduled operation by the association unit and an operation record that relates to the scheduled operation. The scheduled operation described in the document and the operation record are read and converted to an electronic form by an image reading apparatus.
Methods of enabling or improving the ability of a hydrogel to swell in the stomach of an animal and/or increasing the amount of time said hydrogel remains swollen in the stomach are described herein. In one embodiment, a polymer is administered in combination with one or more pH modifying agents which raise and maintain the pH of the micro environment of the polymer and/or the stomach in order inducing swelling in the polymer. The polymer can be a homopolymer, a copolymer, or a polymer blend or composite. In one embodiment, the polymer is a superabsorbent polymer ('SAP'). The polymers can also be administered with one or more active agents, such as appetite suppressants. The pH modifying agent and/or the active agent can be administered simultaneously with the polymer in the same dosage form, simultaneously with the polymer in separate dosage forms, or sequentially. The compositions are formulated for oral administration. The formulation can include drugs for delivery to the stomach, such as antibiotics, or the hydrogel can be used as a filler, for example, for obesity control. The formulation an also be used to enhance gastric retention, for example, for controlled drug delivery. Methods of delivering a drug are also described herein, along with medicaments for carrying out the methods of the present invention.
Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
Thickened liquids are commonly used as an intervention for dysphagia (swallowing impairment). However, the field lacks a clear understanding of how liquids of different consistencies behave during swallowing. In order to improve understanding of the effectiveness of altered liquid consistency for improving dysphagia, the investigators are studying liquid flow through the oropharynx. This study explores this question in individuals with spinal cord injury. Participants will swallow 20% w/v barium thickened to different consistencies (thin, slightly thick, mildly thick, moderately thick and extremely thick). Swallowing will be observed under videofluoroscopy. Simultaneous measures of airflow via nasal cannula will be used to study respiratory-swallow coordination in this study sample.
This is a randomized, double-blind, placebo-controlled, 4-period, 4-week crossover pilot clinical trial consisting of 2 postprandial tests for each period. Overweight or obese postmenopausal women and men aged 40 to 65 will be recruited from the greater Fort Collins, CO area. After telephone prescreening, participants will report to the study site for their first visit (Screening) where they will receive verbal and written explanation of the project, provide informed consent, followed by screening assessments. Qualified participants will be scheduled for a baseline visit and randomly assigned to their respective treatments. On the second visit (Baseline) following an overnight fast, anthropometrics and blood pressure will be measured and diet and physical activity records will be collected. Subjects will ingest their respective treatment 10 min prior to consuming the high-fat test meal. Various assessments will be performed and samples collected prior to and up to 4 hours post-meal consumption. At the third visit (Final), all assessments and sample collections will be repeated at the same time points but 24 hours after consuming the last dose of their respective treatments to test chronic rather than acute effects. Subjects will undergo a 4-week washout period before crossing over to the next treatment period. This will be repeated for all 4 treatments.
A medical monitoring device (5), operating system, and method is provided for managing administration of medical treatment regimens for treating a patient's medical conditions. The device stores information relating to the medical treatment regimens being administered, including medication schedule data, treatment data, patient query data, patient response data, and interactively provides the information to the patient and health care providers (105). A  method and apparatus for performing real-time monitoring of a patient's health status using a medical monitoring device (5) capable of wireless transmission, is also provided. Various aspects of the patient's treatment regimens are modified accordingly. The medical monitoring device (5) further analyzes monitored data in view of predefined criteria, and is capable of promptly communicating information concerning the patient's health status and treatment progress to remote devices (105) which notify appropriate health care providers, and is capable of modifying the patient's treatment regimens based on the results of the analysis. A system of monitoring devices and sensors are further provided for performing real-time monitoring and analysis of the patient's treatment regimens. The wireless monitoring facilitates various real-time tasks including, conducting a health status assessment, monitoring adverse effects experienced by the patient, monitoring treatment progress, assessing physiologic, cellular, molecular, endrocrine, and metabolic data, and assessing the patient's general quality of life.
Benzyl alcohol, a preservative in MESNEX, has been associated with serious adverse reactions and death (including gasping syndrome) in neonates, premature, and low-birth weight infants. The minimum amount of benzyl alcohol at which toxicity may occur is not known. Consider the combined daily metabolic load of benzyl alcohol from all sources when prescribing MESNEX (10.4 mg benzyl alcohol per mL). Neonates, premature, and low-birth weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Monitor patients for signs or symptoms of toxicity. Avoid use in neonates, premature, and low-birth weight infants [See Use in Specific Populations (8.4)].
FIELD: hygiene.SUBSTANCE: group of inventions refers to an oral care composition and a method for preventing syneresis in an oral care composition. Disclosed composition is a dentifrice. Composition contains, wt. % by weight of composition: calcium carbonate - 40–50, alkali metal silicate - 2 or less, thickener - 2 or less, sorbitol - 20–30, potassium nitrate (KNO) - 0.3–0.6, basic amino acid - arginine in free or salt form - 1–5. Method for preventing syneresis in an oral care composition containing calcium carbonate, an alkali metal silicate, a thickener, sorbitol and a basic amino acid in free or salt form involves the addition of an effective amount of potassium nitrate to the oral care composition. Namely, potassium nitrate is added in amount of 0.3–0.6 wt. % by weight of composition, where the composition is a dentifrice and contains, wt. % by weight of composition: calcium carbonate - 40–50, alkali metal silicate - 2 or less, thickener - 2 or less, sorbitol - 20–30, basic amino acid - arginine in free or salt form - 1–5.EFFECT: use of potassium nitrate in said amount provides stability of said composition, preventing manifestation of syneresis.17 cl, 1 tbl, 1 ex
PURPOSE:A dermal external drug, containing urea and further a basic amino acid salt together, capable of improving the stability of the urea in the presence of water with time, and useful for cosmetics or medicines, e.g. a remedy for xeroderma. CONSTITUTION:A dermal external drug, obtained by incorporating a basic amino acid salt, e.g. hydrochloride, hydrobromide, acetate, pyrrolidonecarboxylate or urocanate of a basic amino acid, e.g. histidine, lysine, ornithine or arginine, etc. in an amount of 1/10-3 times that of urea in a dermal external drug containing 0.1-2wt% urea having wetting effect, cell activating effect and wound curing effect, etc., and capable of suppressing the decomposition of the urea in the presence of water and preventing the deterioration of the dermal external drug and pH increase, and having improved stability with time.
This study explored the impact of different maintenance therapies on survival outcomes in patients with multiple myeloma (MM), focusing on changes in minimal residual disease (MRD) during maintenance. Conducted at a single center, this retrospective study included 259 newly diagnosed MM patients who did not undergo autologous stem cell transplantation (ASCT). The results indicated that patients receiving lenalidomide as maintenance therapy showed significantly better progression-free survival (PFS) and overall survival (OS) compared to those treated with bortezomib or no maintenance therapy. However, bortezomib proved more effective in high-risk MM cases. Patients who were MRD-negative prior to starting maintenance therapy had a better prognosis than MRD-positive patients. Notably, lenalidomide was the most effective regimen irrespective of MRD status. Patients maintaining or achieving MRD-negativity within the first year of lenalidomide treatment exhibited improved prognoses, confirming lenalidomide as the optimal maintenance choice.
Calcitonins and calcitonin derivatives such as are employed for therapy for, for example, osteoporosis. Paget's disease or hypercalcemia. The calcitonins and calcitonin derivatives are distinguished by a bridging of the amino acids present in the positions 17 and 21. In this case, by means of a suitable choice of the amino acids present in these positions an 18- or 19-membered ring is produced. This ring leads to an increased conformational stability and to an increased activity of the modified calcitonin. A particularly suitable hCt (human Ct) analog is the cyclo 17,21 -[Asp 17 , Orn 21 ]-hCt according to the invention having a 19-membered ring structure between the lactam-bridged Asp 17  and Orn 21 .
INTRODUCTION: The optimal pain management strategy after open ventral hernia repair (VHR) with transversus abdominus release (TAR) is unknown. Opioids are known to have an inhibitory effect on the GI tract and cause postoperative ileus. Epidural analgesia is associated with lower postoperative ileus rates but may contribute to other postoperative complications. A propensity-matched retrospective review published by our group in 2018 found that epidural analgesia was associated with an increased length of stay and any postoperative complication after VHR. Epidural analgesia was therefore abandoned by our group following this publication. We aimed to determine if discontinuation of epidural analgesia affected ileus rates after open VHR.
METHODS: Patients who underwent open VHR with TAR from August 2014 to January 2022 ​at Cleveland Clinic Foundation with at least 30-day follow-up were retrospectively identified using the Abdominal Core Health Quality Collaborative registry. Patients with and without epidural analgesia were compared. The primary outcome was post-operative ileus. Additional outcomes included length of stay, deep venous thrombosis (DVT), pneumonia, wound complications and pain requiring intervention.
RESULTS: A total of 2570 patients were included: 420 had an epidural, 2150 did not. Preoperative patient and hernia characteristics were similar between both groups. Mean hernia width was 15.5 ​cm in the epidural group and 16.1 ​cm in the no epidural group. In the epidural group, ileus was seen in 9 of 420 (2.15%) of patients which was significantly less than in the no epidural group, 400 of 2150 (18.6%), p=>0.001. On multivariate analysis, epidurals were predictive of lower risk of ileus (OR 0.04, 95%CI 0.01-0.17, p ​= ​0.001) and pain requiring intervention (OR 0.02, 95%CI 0.00-0.71, p ​= ​0.02). Epidural analgesia was not associated with increased DVT rates, pneumonia, length of stay, SSI, or SSOPI.
DISCUSSION: Discontinuation of epidural analgesia was associated with a 9-fold increase in ileus rates after VHR with TAR. Epidurals may play an important role in limiting postoperative opioid use and therefore reducing risk of ileus. Other postoperative complications including pneumonia and venous thrombosis were not impacted by epidurals. Further prospective studies are needed to further define a ventral hernia patient population who will benefit from epidural analgesia.
In this study, the investigator team designs to use self-evaluating form as a tool for any competencies evaluation. The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. The participant could download the self-evaluating form (google form, no personal identity record) via QR code.
The vaginal microbiota has a significant bearing on a woman's mental and physical health at every stage of life. A balanced microflora of the vaginal environment (eubiosis) consists of a predominant presence of lactic acid bacteria. Lactobacilli ensure the maintenance of an acidic pH that effectively makes the environment inhospitable to pathogens by preventing infection and protecting the genital tract. At the end of the reproductive period, the reduction of sex hormones, particularly estrogen, results in a decrease in the lactobacillus component with consequent depletion of the vaginal microbiota and increased susceptibility to pathogens. Tocopherol (vitamin E) is an essential human nutrient found mainly in oily fruits. It is a fat-soluble molecule with high antioxidant power. Topically administered, it not only plays a key role in protecting epithelial cell membranes from oxidative damage but is also able to modulate bacterial growth by contributing to pH acidification. The latter feature, in the vaginal canal, creates a favorable environment for the lactobacilli flora, positively affecting the microbial population and thus contributing to the prevention of all those problems related to increased vaginal sensitivity to pathogens during "menopause." In addition, recent data show that vitamin E can counteract the production of biofilm produced by certain pathogens, which has detrimental effects on the homeostasis of the vaginal environment.

The period of observation is from January 1st, 2020 to December, 31st, 2022, while the Data Collection period will be from June, 30th, 2023 to July, 31st, 2023
Fatal and serious hypersensitivity reactions including anaphylaxis, presenting with cardiac/ cardiorespiratory arrest, clinically significant hypotension, syncope, or unresponsiveness have occurred in patients receiving ferumoxytol. Other adverse reactions potentially associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing). These reactions have occurred following the first dose or subsequent doses in patients in whom a previous ferumoxytol dose was tolerated. 

Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products. Carefully consider the potential risks and benefits before administering ferumoxytol to these patients. 

Only administer ferumoxytol as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions. Closely observe patients for signs and symptoms of hypersensitivity including monitoring of blood pressure and pulse during and after ferumoxytol administration for at least 30 minutes and until clinically stable following completion of each infusion [see Adverse Reactions (6.2)]. 

In a clinical study in patients with IDA, regardless of etiology, hypersensitivity reactions were reported in 0.4% (4/997) of subjects receiving ferumoxytol administered as intravenous infusion over at least 15 minutes. These included one patient with severe hypersensitivity reaction and three patients with moderate hypersensitivity reactions.

In clinical studies predominantly in patients with IDA and CKD, serious hypersensitivity reactions were reported in 0.2% (4/1,806) of subjects receiving ferumoxytol (administered as a rapid intravenous injection – prior method of administration no longer approved). Other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing) were reported in 3.5% (63/1,806) of these subjects. 

In the post-marketing experience, fatal and serious anaphylactic type reactions presenting with cardiac/ cardiorespiratory arrest, clinically significant hypotension, syncope, and unresponsiveness have been reported. Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and/or hypotension following administration of ferumoxytol may have more severe outcomes [see Boxed Warning, Adverse Reactions (6.2) and Use in Specific Populations (8.5)].
The invention relates to an externally-applied medicine for treating burns and scalds and a preparation method thereof. The medicine is composed of a traditional Chinese medicine base solution A and a traditional Chinese medicine powder B, wherein a weight ratio of the traditional Chinese medicine base solution A to the traditional Chinese medicine powder B is 5: 4. The traditional Chinese medicine base solution A and the traditional Chinese medicine powder B are mixed, fully stirred and blended to form paste which is smeared on a wound surface and regularly replaced according to concrete symptoms, so the medicine can be used for treatment of first-degree and second-degree burns and scalds or for adjuvant therapy of third-degree burns and scalds through combination with other conventional measures. The traditional Chinese medicine base solution A comprises the following raw traditional Chinese medicinal materials: 800 g of purslane herb and 100 g of green tea. The traditional Chinese medicine powder B comprises the following raw traditional Chinese medicinal materials: 6 g of dried orange peel, 8 g of alum, 8 g of pericarpium zanthoxyli, 8 g of catechu, 260 g of gentrin knotweed, 15 g of Chinese mahonia leaf, 260 g of Chinese rhubarb, 12 g of chinaroot greenbrier rhizome, 18 g of diverse wormwood herb, 10 g of divaricate saposhnikovia root and 5 g of white bark of cypress. The externally-applied medicine provided by the invention is capable of stopping bleeding, promoting coagulation, eliminating swelling, astringing sores, inhibiting and killing bacteria, relieving pain and engendering flesh and can be used for treatment of first-degree and second-degree burns and scalds or for adjuvant therapy of third-degree burns and scalds through combination with other conventional measures.
Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-200A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Adults with a confirmed diagnosis of Parkinson Disease who have radiographically confirmed difficulties with timely airway protection and/or bolus clearance during swallowing. Individuals will complete a 4-week intervention program with two 30-minute sessions of Effortful Swallow (ES) practice daily, 5 days per week.